+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity



CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity



Oncoimmunology 7(5): E1424677



CD96 is a transmembrane glycoprotein Ig superfamily receptor, expressed on various T cell subsets and NK cells, that interacts with nectin and nectin-like proteins, including CD155/polio virus receptor (PVR). Here, we have compared three rat anti-mouse CD96 mAbs, including two that block CD96-CD155 (3.3 and 6A6) and one that does not block CD96-CD155 (8B10). Using flow cytometry, we demonstrated that both mAbs 3.3 and 6A6 bind to the first Ig domain of mouse CD96 and compete with CD155 binding, while mAb 8B10 binds to the second Ig domain and does not block CD155. While Fc isotype was irrelevant concerning the anti-metastatic activity of 3.3 mAb, in four different experimental metastases models and one spontaneous metastasis model, the relative order of anti-metastatic potency was 6A6 > 3.3 > 8B10. The metastatic burden control of all of the anti-CD96 clones was highly dependent on NK cells and IFN-γ. Consistent with its inability to block CD96-CD155 interactions, 8B10 retained anti-metastatic activity in CD155-deficient mice, whereas 3.3 and 6A6 lost potency in CD155-deficient mice. Furthermore, 8B10 retained most of its anti-metastatic activity in IL-12p35-deficient mice whereas the activity of 3.3 and 6A6 were partially lost. All three mAbs were inactive in CD226-deficient mice. Altogether, these data demonstrate anti-CD96 need not block CD96-CD155 interactions (ie. immune checkpoint blockade) to promote NK cell anti-metastatic activity.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053597356

Download citation: RISBibTeXText

PMID: 29721390

DOI: 10.1080/2162402x.2018.1424677


Related references

The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1. Biochemical and Biophysical Research Communications 364(4): 959-965, 2007

Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). Journal of Immunology 172(7): 3994-3998, 2004

Structural Basis for CD96 Immune Receptor Recognition of Nectin-like Protein-5, CD155. Structure 27(2): 219-228.E3, 2019

CD96 interaction with CD155 via its first Ig-like domain is modulated by alternative splicing or mutations in distal Ig-like domains. Journal of Biological Chemistry 284(4): 2235-2244, 2009

Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96. Plos one 7(8): E42426, 2012

Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Experimental Hematology 26(13): 1209-1214, 1998

CD96 Is an Immune Checkpoint That Regulates CD8 + T-cell Antitumor Function. Cancer Immunology Research 7(4): 559-571, 2019

Interaction between nectin-1 and the human natural killer cell receptor CD96. Plos one 14(2): E0212443, 2019

Cutting edge CD96 promotes NK cell-target cell adhesion by interacting with the poliovirus receptor. Journal of Immunology 172(7): 3994-3998, 2004

CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America 104(26): 11008-11013, 2007

Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia. Archives of Medical Research 45(4): 343-350, 2014

Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma. Hepatology 70(1): 168-183, 2019

Human CD96 gene cloning, expression and identification. Nan Fang Yi Ke Da Xue Xue Bao 31(7): 1232-1235, 2011

Coming of Age: CD96 Emerges as Modulator of Immune Responses. Frontiers in Immunology 9: 1072, 2018

Strategies for purging CD96 + stem cells in vitro and in vivo: New avenues for autologous stem cell transplantation in acute myeloid leukemia. Oncoimmunology 2(6): E24500, 2013